Advanced search×

Vascular Pharmacology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Rcgp, Gale, Sciencedirect, and Ingenta

  1. IGF-1 signaling in neonatal hypoxia-induced pulmonary hypertension: Role of epigenetic regulation

    Vascular Pharmacology 73:20 (2015) PMID 25921925 PMCID PMC4578983

    Pulmonary hypertension is a fatal disease characterized by a progressive increase in pulmonary artery pressure accompanied by pulmonary vascular remodeling and increased vasomotor tone. Although some biological pathways have been identified in neonatal hypoxia-induced pulmonary hyperte...
  2. Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats

    Vascular Pharmacology 73:45 (2015) PMID 26304700

    This study examined the effects of a novel orally active 14,15-epoxyeicosatrienoic acid analog (EET-A) on blood pressure (BP) and myocardial infarct size (IS) in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats during sustained phase of hypertension. Between days 31 and 35 after...
  3. Changes in plasma levels of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine after a single dose of vardenafil in patients with pulmonary hypertension

    Vascular Pharmacology 73:71 (2015) PMID 25934511

    Objective We investigated whether vardenafil, a phosphodiesterase-5 inhibitor, alters plasma levels of asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and arginine.
  4. Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?

    Vascular Pharmacology 73:8 (2015) PMID 26254107

    [Display omitted]
  5. Inside front cover (editorial board members)
    Author(s) unavailable

    Vascular Pharmacology 73:IFC (2015)

  6. Biological actions of pentraxins

    Vascular Pharmacology 73:38 (2015) PMID 25962566

    The innate immunity is the first defense reaction against microorganisms or altered self-components upon tissue injury. Such exogenous or modified endogenous molecules present conserved molecular structures that are recognized by the immune system via pattern-recognition receptors or m...
  7. Epigenetic regulation of insulin-like growth factor signaling: A novel insight into the pathophysiology of neonatal pulmonary hypertension

    Vascular Pharmacology 73:4 (2015) PMID 26254106

    Burdened by high morbidity and mortality, neonatal pulmonary hypertension (PH) is a life-threatening pathophysiological condition that progressively elevates the mean pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR). Pulmonary vascular remodeling and vasoconstric...
  8. Altered expression of P2Y2 and P2X7 purinergic receptors in the isolated rat heart mediates ischemia–reperfusion injury

    Vascular Pharmacology 73:96 (2015) PMID 26070527

    The aim of this study is to analyze the expression of purinergic receptors in the heart after ischemia–reperfusion, and their possible role in ischemia–reperfusion injury. Rat hearts were perfused according to the Langendorff technique and subjected to 30min ischemia followed by 15min ...
  9. Asymmetric dimethyl arginine induces pulmonary vascular dysfunction via activation of signal transducer and activator of transcription 3 and stabilization of hypoxia-inducible factor 1-alpha

    Vascular Pharmacology 73:138 (2015) PMID 26091577

    Pulmonary hypertension (PH), associated with imbalance in vasoactive mediators and massive remodeling of pulmonary vasculature, represents a serious health complication. Despite the progress in treatment, PH patients typically have poor prognoses with severely affected quality of life....
  10. Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors

    Vascular Pharmacology 73:78 (2015) PMID 25921923 PMCID PMC4578990

    Uridine adenosine tetraphosphate (Up4A), a novel endothelium-derived vasoactive agent, is proposed to play a role in cardiovascular disorders and induces aortic contraction through activation of cyclooxygenases (COXs). We and others demonstrated that activation of A1 or A3 adenosine re...